Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This trial will investigate the use of the newer targeted agents erlotinib and sorafenib in
patients with stage IIIB or stage IV NSCLC who have received 1-2 prior chemotherapy regimens.
Patients will be randomized to receive erlotinib (150 mg/day) and sorafenib (400 mg twice
daily), or erlotinib (150 mg/day) and a placebo.